Figure 2

<p><b>Schematic illustration of statistical approach.</b> Panels A and C show approach using non-paired statistics and the DESeq tool. Panel B shows approach using paired statistics and the edgeR tool. See text for further details.</p

Intersect of significant miRs from the adenocarcinoma cases when using non-paired (DESeq) and paired (edgeR) analysis approach.

<p>Adjusted for multiple testing using Benjamini and Hochberg, false discovery rate (FDR) < 0.1. Logarithmic fold change (FC) relative to normal mucosa and FDR from paired analysis using edgeR. miRs also significant in the analysis of the neuroendocrine tumor (NET) is indicated.</p

Read classification as predicted by miRanalyzer and miRBase.

<p>Panel A with percentage of sequencing reads mapped to mature miRs (black) of the total reads per experiment. Panel B with number of mature miRs identified per sequencing experiment. The total number of mature human miRs in miRBase release 16 (n = 1212) is included as reference.</p

Clinical and histopathological characteristics of patients in the study.

<p>Clinical and histopathological characteristics of patients in the study.</p

Venn diagram shows the number of significant miRs identified using the non-paired (DESeq) and paired (edgeR) analysis approach.

<p>Venn diagram shows the number of significant miRs identified using the non-paired (DESeq) and paired (edgeR) analysis approach.</p

Kaplan-Meier curves showing the association between pretreatment plasma YKL-40 and PFS.

<p>For patients with metastatic colorectal cancer included in the NORDIC VII Study. All patients (1A), patients treated in arm A (1B), arm B (1C), and arm C (1D). Patients are dichotomized according to the age-corrected plasma YKL-40 (95 percentile level in healthy subjects). The P-value refers to the log-rank test for equality of strata.</p

Consort diagram indicating sample sizes at each stage during the study.

<p>Consort diagram indicating sample sizes at each stage during the study.</p

Demographic and Baseline Clinical Characteristics of the 510 patients with mCRC included in the Nordic VII Study with pretreatment plasma YKL-40.

<p>Demographic and Baseline Clinical Characteristics of the 510 patients with mCRC included in the Nordic VII Study with pretreatment plasma YKL-40.</p

Expression of is down-regulated in high-risk adenomas and colorectal carcinoma-1

<p><b>Copyright information:</b></p><p>Taken from "Expression of is down-regulated in high-risk adenomas and colorectal carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/7/192</p><p>BMC Cancer 2007;7():192-192.</p><p>Published online 12 Oct 2007</p><p>PMCID:PMC2099434.</p><p></p>h 13 samples categorised as Dukes' A, 19 samples as Dukes' B and 18 samples as Dukes' C. The graph shows the normalised level of mRNA in samples from the different Dukes' stages. Calculating linear regression using each column of data resulted in a statistically significant linear trend (p < 0.05) for a decrease in level with increasing Dukes' stage

Expression of is down-regulated in high-risk adenomas and colorectal carcinoma-0

<p><b>Copyright information:</b></p><p>Taken from "Expression of is down-regulated in high-risk adenomas and colorectal carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/7/192</p><p>BMC Cancer 2007;7():192-192.</p><p>Published online 12 Oct 2007</p><p>PMCID:PMC2099434.</p><p></p>individuals (Control), normal and affected tissue from the same individual with adenomas (low- or high-risk) and colorectal carcinoma. Normal (adjacent): normal sample close to the carcinoma, Normal (distant): normal sample far from the carcinoma. Each dot represents mean values of triplicate determinations. *** p < 0.001 compared to the control group using one-way ANOVA with a Tukey's post test. A trend of decreased expression with increasing tumor grade was observed in affected tissue (p < 0.001)